
Tenax Therapeutics (TENX) Stock Forecast & Price Target
Tenax Therapeutics (TENX) Analyst Ratings
Bulls say
Tenax Therapeutics is a phase three development-stage pharmaceutical company focused on developing therapeutics for cardiovascular and pulmonary diseases, with a specific focus on pulmonary hypertension. Despite secondary and biomarker data showing minimal differences between the subgroup of patients with lower 6WMT at baseline and the overall LEVEL population, the company's prioritized product candidate, Levosimendan, has shown promising results in improving quality of life as measured by KCCQ-TSS and reducing levels of NTproBNP and RSVP.
Bears say
Tenax Therapeutics is a development-stage pharmaceutical company that faces significant risks to commercialize its products successfully. With mixed clinical trial results for its lead product levosimendan and a weak premise for its Phase 3 trials, the company may struggle to gain approval and successfully market the drug. Additionally, there are IP and regulatory risks that could challenge the company's path forward, and with limited funds and a high WACC, the company's stock may not have a favorable outlook for investors.
This aggregate rating is based on analysts' research of Tenax Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tenax Therapeutics (TENX) Analyst Forecast & Price Prediction
Start investing in Tenax Therapeutics (TENX)
Order type
Buy in
Order amount
Est. shares
0 shares